Payment overview · 2025
General Payments
$252.87
14 reported records · 8 companies
Healthcare provider profile · identity verified
Amanda Jill Williams, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · GRIFFIN, GA · NPI 1982097564
Verified facts
What the public records show
CMS Open Payments records show Amanda Jill Williams, NP received $252.87 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.75 | 25.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.80 | 19.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.14 | 13.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.18 | 12.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.82 | 9.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.28 | 8.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.59 | 5.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.31 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.87 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.80 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.80 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 30 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 85 |
| Gabapentin | Gabapentin | 244 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 93 |
| Tramadol Hcl | Tramadol Hcl | 174 | 52 |
| Omeprazole | Omeprazole | 171 | 60 |
| Ozempic | Semaglutide | 167 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 69 |
| Lisinopril | Lisinopril | 152 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 72 |
| Metformin Hcl | Metformin Hcl | 129 | 48 |
| Simvastatin | Simvastatin | 128 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 42 |
| Prednisone | Prednisone | 115 | 85 |
| Alprazolam | Alprazolam | 111 | 28 |
| Furosemide | Furosemide | 111 | 48 |
| Sertraline Hcl | Sertraline Hcl | 106 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 40 |
| Trazodone Hcl | Trazodone Hcl | 99 | 35 |
| Meloxicam | Meloxicam | 93 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 34 |
| Azithromycin | Azithromycin | 85 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 33 |
| Carvedilol | Carvedilol | 78 | 29 |
| Glipizide Er | Glipizide | 78 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 33 |
| Jardiance | Empagliflozin | 73 | 22 |
| Montelukast Sodium | Montelukast Sodium | 73 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 26 |
| Losartan Potassium | Losartan Potassium | 70 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 25 |
| Buspirone Hcl | Buspirone Hcl | 63 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 28 |
| Potassium Chloride | Potassium Chloride | 62 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 22 |
| Eszopiclone | Eszopiclone | 61 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Glipizide | Glipizide | 58 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 15 |
| Eliquis | Apixaban | 55 | 17 |
| Fluconazole | Fluconazole | 55 | 33 |
| Ibuprofen | Ibuprofen | 51 | 19 |
| Allopurinol | Allopurinol | 48 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 18 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 19 |
| Myrbetriq | Mirabegron | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 43 | 16 |
| Ondansetron Odt | Ondansetron | 41 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 30 |
| Lovastatin | Lovastatin | 35 | 13 |
| Sucralfate | Sucralfate | 35 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Famotidine | Famotidine | 31 | 15 |
| Pregabalin | Pregabalin | 31 | 16 |
| Valsartan | Valsartan | 31 | suppressed |
| Linzess | Linaclotide | 30 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 18 |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Glimepiride | Glimepiride | 24 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Colchicine | Colchicine | 19 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 15 |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.87 · 14 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, LINZESS, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error